Heart rhythm disorders are the leading cause of morbidity and mortality in the developed world. Despite a profound difference in physiological mechanisms, anatomic and genetic determinants, and etiology of various arrhythmias, there are only two predominant treatments: electric and ablative therapies. Pharmacological therapy has been mostly ineffective or hampered by side effects. Ablative therapy for atrial tachyarrhythmias is growing in acceptance. However, the ablation procedure is complex, time-consuming, and has a number of side effects. Several modalities of electrotherapy have been effective in preventing sudden cardiac death due to ventricular tachycardia and fibrillation (VT/VF), and in arresting atrial tachycardia and fibrillation (AT/AF). However, the current bioelectric therapy paradigm has a number of limitations. Antitachycardia pacing (ATP) is the most desirable approach due to its low energy requirement, but the efficacy of ATP is limited. High- voltage biphasic shock defibrillation has evolved over the last 70 years as the dominant and highly effective electrotherapy against both AF and VF. However, the energy requirements for AF are suboptimal: high-energy shocks are painful and could cause myocardial damage. In our project we aim to address the limitations of current electrotherapy and present a novel hypothesis: multi-stage phased bioelectric therapy will allow significant reduction in DFT for atrial fibrillaton. Based on previous NIH-funded research from our laboratory we have developed an approach that terminates atrial tachyarrhythmia based on several types of multiple pulse electrotherapies with low, phased (i.e. progressively reducing) energy levels and frequencies: (1) far-field low energy multiple shocks, (2) far-field ultra-low energy entrainment stimulation, and (3) near-field entrainment pacing. We will explore two technological platforms to implement and further investigate our novel method: (1) state-of-the-art lead-based implantable device and (2) flexible electronics developed by the Rogers laboratory at the University of Illinois, Urbana-Champagne. Successful completion of this project will advance implantable bioelectric therapy of cardiac arrhythmias by (1) reducing high-voltage shock induced myocardial damage and post-shock conduction abnormalities secondary to this damage, (2) reducing pain associated with termination of tachyarrhythmias, and (3) reducing energy consumption in the implantable devices. Reduction of the DFT below 0.2J is likely to make implantable atrial defibrillation possible for millions of AF patients. Novel stretchable electronic technology developed by John A. Rogers is likely to transform electrotherapy of cardiac arrhythmias based on high anatomic resolution local sensing and multi-stage therapy of aberrant rhythms.
Atrial fibrillation (AF) is a heart rhythm disorder that affects 3-5 million Americans. There are only two predominant treatments of AF: electric and ablative therapies. High-voltage electric shock defibrillation is the dominant and highly effective electrotherapy against ventricular arrhythmias, but it is not as widely applied against AF, because the high energy shocks are painful and cannot be tolerated by patients. In our project we aim to address the limitations of current electrotherapy and present a novel hypothesis: multi-stage phased bioelectric therapy will allow significant reduction in energy required for AF defibrillation.
|Fang, Hui; Yu, Ki Jun; Gloschat, Christopher et al. (2017) Capacitively Coupled Arrays of Multiplexed Flexible Silicon Transistors for Long-Term Cardiac Electrophysiology. Nat Biomed Eng 1:|
|Vigmond, Edward J; Efimov, Igor R; Rentschler, Stacey L et al. (2017) Fractionated electrograms with ST-segment elevation recorded from the human right ventricular outflow tract. HeartRhythm Case Rep 3:546-550|
|Kang, C; Brennan, J A; Kuzmiak-Glancy, S et al. (2016) Technical advances in studying cardiac electrophysiology - Role of rabbit models. Prog Biophys Mol Biol 121:97-109|
|Koh, Ahyeon; Gutbrod, Sarah R; Meyers, Jason D et al. (2016) Ultrathin Injectable Sensors of Temperature, Thermal Conductivity, and Heat Capacity for Cardiac Ablation Monitoring. Adv Healthc Mater 5:373-81|
|Xu, Lizhi; Gutbrod, Sarah R; Ma, Yinji et al. (2015) Materials and fractal designs for 3D multifunctional integumentary membranes with capabilities in cardiac electrotherapy. Adv Mater 27:1731-7|
|Ripplinger, Crystal M; Efimov, Igor R (2015) Dual Vm/Ca imaging of premature ventricular contractions: bridging the gap of anatomical scales. Circ Arrhythm Electrophysiol 8:529-30|
|Boukens, Bastiaan J; Gutbrod, Sarah R; Efimov, Igor R (2015) Imaging of Ventricular Fibrillation and Defibrillation: The Virtual Electrode Hypothesis. Adv Exp Med Biol 859:343-65|
|Gutbrod, Sarah R; Walton, Richard; Gilbert, Stephen et al. (2015) Quantification of the transmural dynamics of atrial fibrillation by simultaneous endocardial and epicardial optical mapping in an acute sheep model. Circ Arrhythm Electrophysiol 8:456-65|
|Boukens, Bastiaan J; Sulkin, Matthew S; Gloschat, Chris R et al. (2015) Transmural APD gradient synchronizes repolarization in the human left ventricular wall. Cardiovasc Res 108:188-96|
|Villongco, Christopher T; Krummen, David E; Stark, Paul et al. (2014) Patient-specific modeling of ventricular activation pattern using surface ECG-derived vectorcardiogram in bundle branch block. Prog Biophys Mol Biol 115:305-13|
Showing the most recent 10 out of 21 publications